Summit outcomes and next steps
On 15th March, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels, with the aim of setting the vision for Europe’s global innovation, competitiveness, and sustainability on biomanufacturing, while raising awareness among policy-makers. The Summit established a starting point, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs, large companies, expert services, and EU institutions – and which has already started in other parts of the world.
80 attendees from industry, national associations, and stakeholders across the public and private spectrum presented, debated, and proposed. In a fast-moving industrial transition, calls for visionary policies, enabling regulation, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here.
Would you like to find out more?
Join us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions.
Biomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing!
14:00: Welcome and introduction – Claire Skentelbery, Director General, EuropaBio
14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio, Sr Adviser & Programme Manager, EuropaBio
The report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe.
14:20: Report perspectives & reflections from healthcare and biotech industries, and national associations – Sarah Moundir, EU Public Affairs Senior Manager, Novartis | Gwenael Servant, Board Executive, Abolis | Inga Matijosyte, Vice President, LithuaniaBIO
A diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes, as well as the priorities for their companies and organisations.
14:50: Discussion and Q&A with the audience
A discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing.
15:10: Close – Closing remarks.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.